Skip to content
Movie Casting Call
Author:
KAZIA THERAPEUTICS LIMITED.
Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering
August 28, 2026
Kazia Therapeutics Limited Announces Proposed Public Offering
August 28, 2026
Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer
August 28, 2026
Kazia Therapeutics Appoints James Levine as Chief Financial Officer
June 2, 2026
Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
May 26, 2026
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
April 15, 2026
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform
April 13, 2026